2.4. Response and safety evaluation

The efficacy was evaluated according to the IMWG 2016 efficacy evaluation criteria. ¹¹ The efficacy of complete response (CR), very good partial response (VGPR), and partial response (PR) was analyzed. In addition, we also used minimal residual disease (MRD) to evaluate the efficacy for these patients. The sensitivity of our flow cytometry detection for MRD was 10⁻⁵.

Progression‐free survival (PFS) was calculated from the start of treatment to disease progression, death, or the last follow‐up, and overall survival (OS) was calculated from the start of treatment until death or the last follow‐up.

The intensity of adverse events (AEs) was graded and recorded according to the common toxicity standard grading system (National Cancer Institute [NCI] Common Terminology Criteria for Adverse Events [CTCAE], version 5.0).